NCT05552274View on ClinicalTrials.gov

FTIH of ECC4703 in Healthy Volunteers

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 16, 2022

Primary Completion Date

October 26, 2023

Study Completion Date

October 26, 2023

Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
DRUG

ECC4703

ECC4703 will be administered as 1 mg, 10 mg and 40 mg capsules. ECC4703 will be administered as oral capsules during each dosing day.

DRUG

Placebo

Matching Placebo will be administered as oral capsules. Matching Placebo will be given orally during each dosing day.

Trial Locations (1)

89113

Eccogene Investigational Site, Las Vegas

Sponsors

Lead Sponsor

Eccogene
All Listed Sponsors
lead

Eccogene

INDUSTRY

NCT05552274 - FTIH of ECC4703 in Healthy Volunteers | Biotech Hunter | Biotech Hunter